Comparative Pharmacology
Head-to-head clinical analysis: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE versus KLOXXADO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE versus KLOXXADO.
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE vs KLOXXADO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that is added to deter intravenous abuse.
KLOXXADO (flumazenil) is a benzodiazepine antagonist that competitively inhibits the activity at the benzodiazepine binding site on the GABA-A receptor, thereby reversing the effects of benzodiazepines.
Sublingual tablet: initially 2/0.5 mg buprenorphine/naloxone, titrated to maintenance 4/1 mg to 24/6 mg once daily; administered sublingually as a single daily dose.
5 mg intranasally as a single dose; may repeat once after 2-3 minutes if response inadequate.
None Documented
None Documented
Buprenorphine: terminal half-life 24-60 hours (mean ~37h) due to slow dissociation from mu-opioid receptors; naloxone: ~2-12 hours (mean ~1-2h IV, slightly longer sublingual).
Terminal elimination half-life is approximately 2 hours (range 1-4 hours); clinical context: short half-life supports rapid reversal of opioid effects but requires monitoring for renarcotization, especially with long-acting opioids.
Buprenorphine: ~70% fecal via biliary excretion, ~30% renal as unchanged drug and metabolites. Naloxone: primarily hepatic metabolism, ~50% renal excretion of metabolites within 6h.
Hepatic metabolism primarily via CYP3A4 to inactive metabolites; renal excretion accounts for <1% of unchanged drug; fecal excretion accounts for approximately 50-60% of the dose as metabolites.
Category A/B
Category C
Opioid Antagonist
Opioid Antagonist